22:56 , Nov 2, 2016 |  BC Extra  |  Financial News

Veracyte raises $30M in follow-on

Molecular diagnostics company Veracyte Inc. (NASDAQ:VCYT) raised $30 million through the sale of 5 million shares at $6 in a follow-on underwritten by Leerink and BTIG. The price is a 16% discount to Veracyte's $7.13...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Financial News

Envisia Therapeutics financial update

Envisia Therapeutics Inc. , Research Triangle Park, N.C.   Business: Ophthalmic   Date announced: 2016-03-23   Note: Envisia raised $16.5 million in an extension of a series A round, bringing the total raised in the...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

ENV515: Phase IIa data

An open-label, U.S. Phase IIa trial in 21 patients with bilateral ocular hypertension or early primary open-angle glaucoma showed that a single dose of ENV515 met the primary endpoint of reducing diurnal IOP at day...
01:19 , Oct 7, 2015 |  BC Extra  |  Clinical News

Envisia's ENV515 matches Travatan Z in glaucoma study

Envisia Therapeutics Inc. (Research Triangle Park, N.C.) said ENV515 met the primary endpoint in a Phase IIa trial to treat glaucoma. The extended-release formulation of travoprost significantly reduced intraocular pressure (IOP) in the dose-ranging study,...
01:19 , Jun 19, 2015 |  BC Extra  |  Company News

Management tracks

Gene therapy company AveXis Inc. (Dallas, Texas) hired Sean Nolan as CEO. He replaces John Carbona, who resigned in April. Nolan was CBO at InterMune Inc. , which Roche (SIX:ROG; OTCQX:RHHBY) acquired. Ophthalmic company Envisia...
02:23 , Apr 16, 2015 |  BC Extra  |  Company News

Management tracks

Merck KGaA (Xetra:MRK) said Udit Batra will become head of its combined life sciences business, pending completion in mid-2015 of its planned acquisition of Sigma-Aldrich Corp. (NASDAQ:SIAL). Batra has been CEO and president of Merck...
01:34 , Mar 11, 2015 |  BC Extra  |  Company News

Management tracks

Oncology play Bind Therapeutics Inc. (NASDAQ:BIND) named Andrew Hirsch as acting president and CEO. Hirsch, formerly Bind's COO and CFO, replaces Scott Minick, who will remain on Bind's board. The company also appointed Dan Koerwer...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

Liquidia, Lq3 dental, drug delivery news

Liquidia spun out Lq3 to develop therapies for oral health conditions using Liquidia's Particle Replication in Non-Wetting Templates (PRINT) drug delivery technology. Lq3 has an undisclosed oral health product in preclinical testing. Lq3's CEO is...
07:00 , Jul 21, 2014 |  BioCentury  |  Emerging Company Profile

Envisia: Ophthalmic nanotechnology

Envisia Therapeutics Inc. is using its PRINT microparticle formulation technology to develop sustained-release, implantable versions of approved drugs for glaucoma and age-related macular edema. The products could solve compliance problems with existing therapeutics and could...
08:00 , Feb 20, 2014 |  BC Innovations  |  Cover Story

Europe's upwelling

SciBX 's third annual comprehensive analysis of public-private partnerships and early stage venture financing activity shows that Europe's public-private partnership activity in 2013 surpassed that of the U.S. in dramatic fashion. At least 314 companies...